November 20, 2018

RNA sequencing identifies differences in immune profiles of tumors from pediatric neuroblastoma patients with Opsoclonus myoclonus syndrome

RNA sequencing for insights into immuno-oncology research
Opsoclonus myoclonus syndrome (OMS) is a rare, paraneoplastic neurological disorder that presents in 2-3% of pediatric neuroblastoma (NBL) cases.

NBL patients presenting with OMS have a 70-80% survival rate. OMS-associated neuroblastomas have demonstrated increase lymphocyte infiltration, but little is known about the molecular basis of this disorder.

Download our poster, presented at the 2018 EORTC-NCI-AACR, which highlights our goal to utilize RNA sequencing in order to better understand the genomic difference between NBL tumors from patients with and without OMS.

Related Services:
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 15 Immune Landscape Signatures

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Microsatellite Instability Assay for Response to Immunotherapy

MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens

T-cell Receptor (TCR) Sequencing Assay for Characterization of Adaptive Immune Response

Detects TCRβ and TCRγ clonotypes expressed at the mRNA level

Read More